What are the specific side effects of 5‑fluorouracil, oxaliplatin, and pembrolizumab?

Specific Side Effects of 5-Fluorouracil, Oxaliplatin, and Pembrolizumab

Each of these agents has distinct toxicity profiles: 5-FU causes gastrointestinal toxicity, hand-foot syndrome, and cardiotoxicity; oxaliplatin produces characteristic acute and chronic neuropathy plus hematologic toxicity; and pembrolizumab generates immune-related adverse events affecting multiple organ systems, with the combination of these agents increasing risks of diarrhea, pneumonitis, and hepatotoxicity. 1, 2

5-Fluorouracil (5-FU) Specific Side Effects

Gastrointestinal Toxicity

• Diarrhea and mucositis are among the most common dose-limiting toxicities, with 5-FU contributing significantly more to gastrointestinal toxicity than oxaliplatin when used in combination 3
• Oral mucositis occurs frequently and requires supportive care measures 4

Dermatologic Effects

• Hand-foot syndrome (palmar-plantar erythrodysesthesia) is a characteristic toxicity of 5-FU 4
• Cutaneous adverse effects including rash and other skin reactions occur commonly 4

Ocular Toxicity

• Excessive lacrimation occurs in approximately 30% of patients, with 5-FU appearing in tears at concentrations of 16-23.8 μg/mL within 15 minutes of IV administration 5
• Irritation and fibrosis of the tear duct can develop from direct drug exposure in lacrimal fluid 5

Cardiovascular Toxicity

• Cardiotoxicity is a recognized adverse effect of 5-FU 4
• Neurovascular toxicity including cerebral vasospasm with transient ischemia can present as stroke-like symptoms, representing a rare but critical adverse effect 6

Hematologic Effects

• Myelosuppression including neutropenia and anemia occurs with 5-FU therapy 4

Oxaliplatin Specific Side Effects

Neurologic Toxicity (Most Characteristic)

• Acute sensory neuropathy develops rapidly, often triggered or exacerbated by cold exposure 1, 3
• Cumulative sensory neuropathy occurs after multiple cycles, affecting approximately 75% of patients but is reversible in most cases with a median recovery time of 13 weeks after discontinuation 3
• Peripheral neuropathy occurred in 15% of patients (5% grade 3-4) in combination therapy 1

Hematologic Toxicity

• Grade 3/4 neutropenia occurred in 41.7% of patients receiving FOLFOX-4 regimen 3
• Neutropenia: 81% all grades (53% grade 3-4) in previously untreated advanced colorectal cancer 1
• Leukopenia: 85% all grades (20% grade 3-4) 1
• Thrombocytopenia is rare but can occur after multiple cycles, affecting 71% all grades (5% grade 3-4) 1, 3
• Anemia: 81% all grades (2% grade 3-4) 1

Gastrointestinal Effects

• Nausea and vomiting are usually mild to moderate and readily controlled with standard antiemetics 3
• Diarrhea: 60% all grades (4% grade 3-4), though 5-FU contributes more significantly to this toxicity 1, 3

Hepatic Toxicity

• Elevated liver enzymes including AST (47% all grades) and ALT (31% all grades) 1
• Hyperbilirubinemia: 6% all grades (1% grade 3-4) 1

Pulmonary Toxicity

• Pulmonary fibrosis is rare (less than 1% of patients) but can be fatal 1
• Rapidly developing pulmonary fibrosis has been reported with FOLFOX regimen, though no established management guideline exists 7
• Interstitial lung disease (sometimes fatal) has been reported in postmarketing surveillance 1

Renal Effects

• Nephrotoxicity has not been reported in oxaliplatin trials, allowing administration without hydration 3
• However, postmarketing reports include acute tubular necrosis, acute interstitial nephritis, and acute renal failure 1

Other Notable Effects

• Injection site reactions including redness, swelling, pain, and rare skin necrosis with extravasation 1
• Posterior reversible encephalopathy syndrome (PRES) in less than 0.1% of patients 1

Pembrolizumab Specific Side Effects

Immune-Related Adverse Events (irAEs)

When combined with chemotherapy, pembrolizumab increases specific toxicities compared to chemotherapy alone: 2

Pulmonary

• Pneumonitis shows the highest risk ratio (RR 2.79) for all-grade events when combining immunotherapy with chemotherapy, representing the most common serious adverse event with anti-PD1 treatments 2
• Grade ≥3 dyspnea: RR 1.87 (significantly increased) 2

Dermatologic

• Rash demonstrates substantial increase: all-grade RR 1.56, grade 3-4 RR 2.58 2
• Skin toxicity is more common with immunotherapy than chemotherapy 2

Endocrine

• Thyroid dysfunction shows marked increase: RR 2.13 for all grades, representing one of the most common irAEs 2
• Endocrine toxicity is characteristic of immunotherapy rather than chemotherapy 2

Gastrointestinal/Hepatic

• Elevated liver enzymes: grade ≥3 RR 1.56, reflecting immune-mediated hepatitis 2
• Diarrhea: grade ≥3 RR 1.42, likely from combined gut microbiome disturbance and immune-mediated colitis 2
• Enterocolitis is more common with immunotherapy 2

Other Immune-Related Effects

• Myocarditis (rare but potentially fatal) 2
• Arthralgia is more common with immunotherapy 2
• Uveitis occurs specifically with immunotherapy 2

Hematologic Effects (When Combined with Chemotherapy)

• Neutropenia: all-grade RR 1.11 (modest increase) 2
• Anemia, thrombocytopenia show minimal additional risk when adding immunotherapy 2

Combination Therapy Considerations

Synergistic Toxicities

When pembrolizumab is combined with 5-FU and oxaliplatin (as in FOLFOX regimens), specific toxicities are amplified: 2

• Grade 3-4 diarrhea increases significantly (RR 1.42), likely from combined mechanisms of chemotherapy-induced damage and immune-mediated colitis plus gut microbiome disturbance 2
• Pneumonitis and dyspnea risk increases substantially, requiring heightened vigilance 2
• Hepatotoxicity increases as both oxaliplatin and pembrolizumab can cause liver injury through different mechanisms 2
• Grade 3 immune-mediated adverse events occurred in approximately 5 patients in recent combination studies 8

Important Clinical Pitfalls

• The incidence of adverse events in combination therapy is only slightly higher than chemotherapy alone, indicating absence of a fully additive effect for most toxicities 2
• One death related to pneumocystis pneumonia occurred in a recent trial combining spartalizumab (anti-PD-1) with FLOT, highlighting infection risk 8
• Severe post-surgery complications occurred in 23% of patients receiving perioperative immunotherapy-chemotherapy combinations 8
• Treatment delays for toxicity and dose reductions were required in 21% and 42% of patients respectively in combination regimens 8